Phase I Dose-Escalation Study of Once Weekly or Once Every Two Weeks Administration of High-Dose Sunitinib in Patients With Refractory Solid Tumors | Zendy

Maria Rovithi | Zendy; Sophie L. Gerritse | Zendy; Richard J. Honeywell | Zendy; Albert J. ten Tije | Zendy; Rita Ruijter | Zendy; Godefridus J. Peters | Zendy; Jens Voortman | Zendy; Mariëtte Labots | Zendy; Henk M.W. Verheul | Zendy

Open Access

Phase I Dose-Escalation Study of Once Weekly or Once Every Two Weeks Administration of High-Dose Sunitinib in Patients With Refractory Solid Tumors

Author(s) -

Maria Rovithi,

Sophie L. Gerritse,

Richard J. Honeywell,

Albert J. ten Tije,

Rita Ruijter,

Godefridus J. Peters,

Jens Voortman,

Mariëtte Labots,

Henk M.W. Verheul

Publication year - 2018

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.18.00725

Subject(s) - medicine , tolerability , adverse effect , nausea , refractory (planetary science) , sunitinib , dosing , regimen , surgery , cancer , gastroenterology , physics , astrobiology

Dose and schedule optimization of treatment with tyrosine kinase inhibitors is of utmost importance. On the basis of preclinical data, a phase I clinical trial of once weekly or once every 2 weeks administration of high-dose sunitinib in patients with refractory solid malignancies was conducted.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research